X4 Pharmaceuticals (XFOR) Other Non-Current Liabilities (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Other Non-Current Liabilities for 10 consecutive years, with $523000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities fell 2.24% year-over-year to $523000.0; the trailing twelve-month figure through Jun 2026 stood at $523000.0 (down 2.24% YoY), and the FY2025 full-year result was $977000.0, down 92.9% from the prior year.
• Other Non-Current Liabilities slipped to $523000.0 in Q2 2026 per XFOR's latest filing, from $897000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $47.2 million in Q2 2023 and bottomed at $312000.0 in Q3 2022.
• Historically, Other Non-Current Liabilities has averaged $11.0 million across 5 years, with a median of $6.1 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities jumped 14925.16% in 2023, then sank 94.2% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $23.1 million in 2022, then slumped by 32.23% to $15.7 million in 2023, then decreased by 12.29% to $13.8 million in 2024, then plunged by 92.9% to $977000.0 in 2025, then plunged by 46.47% to $523000.0 in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $523000.0, $897000.0, and $977000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.